Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics... Show more
Industry Biotechnology
A.I.dvisor tells us that ORYZF and REPL have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ORYZF and REPL's prices will move in lockstep.
| Ticker / NAME | Correlation To ORYZF | 1D Price Change % | ||
|---|---|---|---|---|
| ORYZF | 100% | N/A | ||
| REPL - ORYZF | 30% Poorly correlated | +0.12% | ||
| TVGN - ORYZF | 24% Poorly correlated | +1.55% | ||
| GNNSF - ORYZF | 24% Poorly correlated | N/A | ||
| IBIO - ORYZF | 23% Poorly correlated | -0.32% | ||
| BMRN - ORYZF | 23% Poorly correlated | -0.03% | ||
More | ||||